KPC(SH:600422) SINOLINK SECURITIES·2026-03-20 03:24Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its long-term development prospects [5]. Core Insights - The company reported a revenue of 6.575 billion RMB in 2025, a decrease of 21.7% year-on-year, and a net profit attributable to shareholders of 350 million RMB, down 46.0% year-on-year [3][5]. - The company's performance is under pressure due to multiple factors, including slow progress in the centralized procurement of traditional Chinese medicine and deepening medical insurance cost control policies, which have impacted existing business [4]. - The company has seen a significant decline in oral medication revenue, which was 2.31 billion RMB in 2025, down 37.4% year-on-year, while injection revenue was 610 million RMB, an increase of 12.6% year-on-year [4]. Summary by Sections Performance Review - In Q4 2025, the company achieved a revenue of 1.824 billion RMB, a decline of 29.9% year-on-year, with a net profit of 81 million RMB, down 60.4% year-on-year [3]. - The listing of a subsidiary, Weili Zhizhi, contributed approximately 119 million RMB to the company's net profit [3]. Operational Analysis - The retail sector is undergoing adjustments, leading to intensified competition and affecting customer traffic and sales momentum [4]. - The company has received authoritative recognition for several products, enhancing its brand image in the academic community [4]. Profit Forecast and Valuation - The net profit forecasts for 2026 and 2027 have been adjusted to 214 million RMB and 350 million RMB, respectively, with a projected net profit of 496 million RMB in 2028 [5]. - The earnings per share (EPS) are expected to be 0.28 RMB, 0.46 RMB, and 0.65 RMB for 2026, 2027, and 2028, respectively, with corresponding price-to-earnings (P/E) ratios of 42, 26, and 18 times [5].